A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients.
PF-04449913 will be administered orally as a single agent in patients with select advanced
hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and
daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or high-risk
MDS [Myelodysplastic Syndrome], or in combination with azacitidine in previously untreated
patients with AML.